Results 31 to 40 of about 3,471,294 (187)

Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance in <i>Pseudomonas aeruginosa</i>. [PDF]

Antimicrob Agents Chemother
A wide variety of clinically observed amino acid alterations in the Pseudomonas aeruginosa chromosomal β-lactamase AmpC (Pseudomonas-derived cephalosporinase [PDC]) are associated with increased resistance to cefepime, ceftolozane/tazobactam, or ...
González-Pinto L, Gomis-Font MA, Lence E, Outeda-García M, Blanco-Martín T, Rodríguez-Pallares S, Sánchez-Peña L, Alonso-García I, Vázquez-Ucha JC, Beceiro A, Bou G, González-Bello C, Oliver A, Arca-Suárez J.   +13 more
europepmc   +2 more sources

Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence ISAba36 in the siderophore receptor pirA. [PDF]

Antimicrob Agents Chemother
We report the emergence of cefiderocol resistance in a blaOXA-72 carbapenem-resistant Acinetobacter baumannii isolate from a sacral decubitus ulcer.
Huang E, Thompson RN, Moon SH, Keck JM, Lowry MS, Melero J, Jun S-R, Rosenbaum ER, Dare RK.   +8 more
europepmc   +2 more sources

Emergence of cefiderocol resistance during ceftazidime/avibactam treatment caused by a large genomic deletion, including <i>ampD</i> and <i>piuCD</i> genes, in <i>Pseudomonas aeruginosa</i>. [PDF]

Antimicrob Agents Chemother, 2023
We report the emergence of cefiderocol resistance during the treatment of a ST312 Pseudomonas aeruginosa respiratory infection with ceftazidime/avibactam.
Gomis-Font MA, Clari MA, López-Causapé C, Navarro D, Oliver A.   +4 more
europepmc   +2 more sources

Rapid Emergence of Cefiderocol Resistance Associated with Mutation of <i>EnvZ</i> Gene in a VIM-Producing ST307 <i>Klebsiella pneumoniae</i> Strain. [PDF]

Antibiotics (Basel)
Infections caused by carbapenem-resistant Enterobacterales (CRE), particularly those harboring metallo-β-lactamases (MBLs) such as VIM, constitute a significant public health threat due to the paucity of effective therapeutic options.
Ambretti S, Secci B, Cetatean R, Gatti M, Viale P, Pea F, Foschi C.   +6 more
europepmc   +2 more sources

In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA [PDF]

Microbiology Spectrum, 2021
By serially exposing an NDM-producing Klebsiella pneumoniae clinical strain to cefiderocol, we obtained a mutant with cefiderocol MIC of >128 μg/ml. The mutant contained an early stop codon in the iron transporter gene cirA, and its complementation fully
Christi L. McElheny, Erin L. Fowler, Alina Iovleva, Ryan K. Shields, Yohei Doi   +4 more
doaj   +2 more sources

Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing <i>Escherichia coli</i> bloodstream isolate exhibiting reduced susceptibility to both agents at baseline. [PDF]

JAC Antimicrob Resist
Background Cefiderocol (FDC) or ceftazidime-avibactam with aztreonam (CZA-ATM) are frontline agents for New Delhi metallo-β-lactamase (NDM)-producing Enterobacterales; however, clinical data are scarce, and mechanisms of treatment-emergent resistance are
Haidar G, Kline EG, Kitsios GD, Wang X, Kwak EJ, Newbrough A, Friday K, Hughes Kramer K, Shields RK.   +8 more
europepmc   +2 more sources

Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression. [PDF]

Clin Infect Dis, 2022
BACKGROUND As cefiderocol is increasingly being prescribed in clinical practice, it is critical that we understand key mechanisms contributing to acquired resistance to this agent.
Simner PJ, Mostafa HH, Bergman Y, Ante M, Tekle T, Adebayo A, Beisken S, Dzintars K, Tamma PD.   +8 more
europepmc   +2 more sources

Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract [PDF]

Therapeutic Advances in Urology, 2022
Cefiderocol is a unique siderophore cephalosporin antimicrobial agent that has shown promise in treating complicated urinary tract infections (cUTI). Urinary tract infections are commonly diagnosed infections with risk increasing with age and prevalence ...
Hongmei Wang, Brittany N. Palasik
doaj   +3 more sources

Unraveling Cefiderocol Resistance in NDM- and OXA-48-like Co-Producing Klebsiella pneumoniae Isolates Through Integrated Genomic and Phenotypic Analysis [PDF]

Antibiotics
Background/Objectives: The co-production of New Delhi metallo-β-lactamases (NDM) and OXA-48-like carbapenemases in Klebsiella pneumoniae represents a major therapeutic challenge due to extensive drug resistance and limited treatment options.
Simone Ambretti, Raul Cetatean, Benedetta Secci, Jessica Landi, Alessia Cantiani, Claudio Foschi   +5 more
doaj   +2 more sources

Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii [PDF]

European Journal of Clinical Microbiology & Infectious Diseases, 2023
Abstract Purpose Due to its ability to disseminate worldwide and its multiple resistance trait, Acinetobacter baumannii is becoming a threat for public health worldwide. Cefiderocol (FDC) is a promising broad-spectrum cephalosporin recently approved for treating Gram-negative infection.
Otávio Hallal Ferreira Raro, Maxime Bouvier, Auriane Kerbol, Jean‐Winoc Decousser, Laurent Poirel, Patrice Nordmann   +5 more
openalex   +4 more sources